Auris Medical Hld

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the following geographical segments: United States, Switzerland, Europe, and Australia. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

Hamilton, Bermuda, July 15, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the launch of its newly-designed corporate website www.aurismedical.com. The new website features a streamlined and modern design and also reflects the Company's recently announced strategic repositioning.

Auris Medical Announces Launch of New Corporate Website

AcelRx Pharmaceuticals

Banco Bradesco

Camber Energy

Verb Technology Company Inc

Are these Reddit penny stocks worth adding to your small-caps watchlist right now? The post 5 Reddit Penny Stocks to Watch That Are Moving Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Reddit Penny Stocks to Watch That Are Moving Right Now

Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional preclinical data in a primary human nasal airway epithelium model from its Bentrio (AM-301) nasal spray for COVID-19. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation.

Auris Medical's Bentrio Nasal Spray Shows Encouraging Preclinical Action In Prevention, Mitigation Of COVID-19

Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it significantly decelerated viral titer growth in experimental models of prophylaxis and mitigation. The manuscript describing these preclinical data is available on a preprint server at https://www.biorxiv.org/content/10.1101/2021.07.12.452021v1 and will undergo scientific peer-review for potential publication.

Auris Medical Announces Publication of Data from Preclinical Studies with Bentrio™ Nasal Spray in Prevention and Mitigation of SARS-CoV-2

Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform. The Company intends to develop the treatment under project code AM-401 with submission of an IND targeted for the end of 2022.

Auris Medical to Develop KRAS-Targeting RNA Treatment for Colorectal Cancer as First Therapeutic Indication for OligoPhore™ Technology

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries.

Auris Medical to Initiate Market Launch of Bentrio™ Nasal Spray in Germany

The stock price of Auris Medical Holding Ltd. (NASDAQ: EARS) increased by over 14% pre-market.

EARS Stock Price Increases Over 14% Pre-Market

Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the publication of positive results from an in vivo study demonstrating significant inhibition of tumor growth by siRNA knock-down of NF-κB employing its OligoPhoreTM technology in Adult T-cell Leukemia Lymphoma (ATLL). The article titled "Targeting NF-κB with nanotherapy in a mouse model of adult T-cell leukemia / lymphoma” was published in Nanomaterials, an international peer-reviewed open-access journal.1

Auris Medical Announces Significant Inhibition of Tumor Growth with OligoPhore siRNA Targeting NF-κB in Murine Model of Adult T-Cell Leukemia / Lymphoma

Auris Medical Holding Ltd (NASDAQ:EARS) shares are trading higher by 12.7% at $4.16 Thursday morning after the company announced the acquisition of RNA therapeutics company Trasir Therapeutics and plans for strategic repositioning. Auris Medical Holding is a clinical-stage biopharmaceutical company that develops therapeutics that address important unmet medical needs in neurotology, rhinology, allergy and CNS disorders.

Why Auris Medical Stock Is Moving Today

Auris Medical Holding Ltd (NASDAQ: EARS) has acquired privately-held Trasir Therapeutics Inc, focused on extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares, the assumption of certain selling shareholders' cash outlays, as well as a future share-based payment contingent on reaching a specific development milestone.

Auris Medical Enters RNA Therapeutics with Trasir Therapeutics Acquisition; Plans To Spin-Off/Divest Existing Programs

The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by over 9% pre-market. This is why it happened.

EARS Stock Price: Over 9% Increase Pre-Market Explanation

Hamilton, Bermuda, June 3, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced the acquisition of privately held Trasir Therapeutics, Inc. (“Trasir”), based in Tampa, FL, a pioneer in extrahepatic oligonucleotide delivery. The purchase price comprises 0.77 million common shares of the acquiring Company, the assumption of certain selling shareholders' cash outlays as well as a future share-based payment contingent on reaching a specific development milestone. The transaction, which closed on June 1, 2021, is the starting point for a strategic repositioning under which the Company intends to focus on the development of RNA therapeutics while in the medium term aiming to spin off or divest its existing assets in neurotology, rhinology and allergology. Dr. Samuel Wickline, Trasir's founder and Professor of Medicine, has been appointed Chief Scientific Officer and joined the Company's leadership team.

Auris Medical Announces Acquisition of RNA Therapeutics Company and Plans for Strategic Repositioning

Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its BentrioTM nasal spray for protection against airborne viruses and allergens in India. The study will seek to evaluate the efficacy of BentrioTM in the prevention and treatment of acute Covid-19 and shall start recruitment in the third quarter 2021 subject to regulatory and ethics committee approval.

Auris Medical Starts Preparations for Covid-19 Trial with Bentrio in India

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com.

Auris Medical Holding to Present at LD Micro Invitational XI Conference

Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced that it has successfully completed the conformity assessment procedure for marketing the BentrioTM nasal spray in the member states of the European Union (EU). The product, which is intended to help protect against airborne allergens and viruses, is considered a Class I medical device under the Medical Devices Directive (MDD). BentrioTM therefore meets all essential requirements for marketing BentrioTM across Europe under the so-called CE mark.

Auris Medical Announces Completion of Bentrio Conformity Assessment Procedure for Marketing in EU

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo.

Auris Medical Reaches Midpoint for Enrollment in Part B of AM-125 Phase 2 TRAVERS Trial in Acute Peripheral Vertigo

Since late January, each time shares of Auris Medical Holding Ltd. (NASDAQ:EARS) fell to $2.80 a rally followed.

Auris Medical Falls To Support And Rallies

Peabody Energy

Checkpoint Therapeutics

Ebang International Holdings

Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Meme Penny Stocks To Watch As DogeCoin Rises

Auris Medical Holding Ltd (NASDAQ: EARS) has announced additional information regarding the results from the clinical trial of its nasal spray, Bentrio, meant for treating people suffering from allergic rhinitis. Additionally, the company also provided an essential update about the regulatory path for the product in the U.S.

Auris Medical Stock Is Trading Higher As Bentrio Hit Primary Endpoint Goal In Allergic Rhinitis Study

The stock price of Auris Medical Holding Ltd (NASDAQ: EARS) increased by over 30% during intraday trading. This is why it happened.

EARS Stock: Over 30% Increase Intraday Explanation

Hamilton, Bermuda, May 7, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced additional details on the outcomes from the clinical investigation of its BentrioTM nasal spray in allergic rhinitis and provided an update on the regulatory pathway in the US for the intended use in allergy.

Auris Medical Provides Update on Bentrio Program in Allergy

Hamilton, Bermuda, April 13, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today provided an update on its AM-301 program for protection against airborne viruses and allergens.

Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch

EARS Stock: Over 9% Increase Pre-Market Explanation

CytoDyn Inc.

Prometheus Biosciences

Auris Medical Holding Ltd. (NASDAQ: EARS), CytoDyn Inc. (OTC: CYDY) and Prometheus Biosciences, Inc. (NASDAQ: RXDX) are among the biggest movers in the biopharma space Thursday.

Why Auris Medical, CytoDyn and Prometheus Shares Are Moving Today

Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it will provide a business update on its AM-301 program for protection against airborne viruses and allergens on Tuesday, April 13, 2021. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time).

News for Auris Medical Hld Stock (EARS)